In contrast, low expression of caveolin-1, a tumor-suppressor gene, in CAFs predicts adverse outcomes in GC, showing that caveolin-1 in CAFs is probably a useful negative prognostic marker [81]. The gene discussed is CAV1; the disease is gastric cancer.